Skip to main content

Month: September 2023

Dental CAD/CAM Market Size to Surpass USD 4.92 Billion by 2030, exhibiting a CAGR of 9.3%

As per the report by Fortune Business Insights, the global dental CAD/CAM market size is projected to reach USD 4.92 billion in 2030, at a CAGR of 9.3% during the forecast period, 2023-2030Dental CAD/CAM MarketDental CAD/CAM Market Forecast(2023-2030)Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) — Global dental CAD/CAM market size was valued at USD 2.22 billion in 2022 and market is projected to grow USD 4.92 billion by 2030, exhibiting a CAGR of 9.3% during forecast period. The increasing prevalence of dental diseases and rising awareness regarding latest technologies to design dental prostheses propel the market growth.  Fortune Business Insights™ mentioned this in a report titled “Dental CAD/CAM Market, 2023-2030.”Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/dental-cad-cam-market-105080...

Continue reading

NorthWest Copper Provides Update on Board Transition

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — NorthWest Copper Corp. (TSXV: NWST) (OTCQX: NWCCF) (“NorthWest” or the “Company”) is pleased to provide an update on the transition of the Company under the stewardship of its newly elected Board of Directors (the “Board”). The Board has elected Mr. Grant Sawiak as its Chair. The Board will be working closely with existing management to address the concerns of the shareholders and to move the Company forward in the interest of all stakeholders. To this end, the Board has formed a Technical Committee comprising Messrs. Jim Steel and John Theobald to urgently review all available technical information of NorthWest’s Copper properties (the “Projects”). The Technical Committee will work with senior management to recommend the Company’s technical strategy that will ensure...

Continue reading

Orthopedic Devices Market Size to Surpass USD 80.28 Billion by 2030, exhibiting a CAGR of 4.5%

As per the report by Fortune Business Insights, the global Orthopedic Devices Market size is projected to reach USD 80.28 billion in 2030, at a CAGR of 4.5% during the forecast period, 2023-2030Orthopedic Devices MarketOrthopedic Devices Market Forecast 2023-2030Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) — Global Orthopedic Devices Market Size was valued at USD 56.84 billion in 2022 and is projected to grow USD 80.28 billion by 2030, exhibiting a CAGR of 4.5% during the forecast period. The expansion can be credited to the growing elderly population, which is expected to increase the surgical volume. This information is provided by Fortune Business Insights™ in its research report titled Orthopedic Devices Market, 2023-2030.Key Industry Development-January 2023: Orthofix US LLC, a medical device company,...

Continue reading

Dermatophytic Onychomycosis Treatment Market Size to Surpass USD 8.64 Billion by 2030, exhibiting a CAGR of 8.0%

As per the report by Fortune Business Insights, the global Dermatophytic Onychomycosis Treatment Market size is projected to reach USD 8.64 billion in 2030, at a CAGR of 8.0% during the forecast period, 2023-2030Dermatophytic Onychomycosis Treatment MarketDermatophytic Onychomycosis Treatment Market (2023-2030)Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) — According to Fortune Business Insights, the global Dermatophytic Onychomycosis Treatment Market Size was valued at USD 4.68 billion in 2022 and is projected to grow from USD 5.05 billion in 2023 to USD 8.64 billion by 2030, exhibiting a CAGR of 8.0% during the forecast period. The expansion can be credited to the growing geriatric population. Various research studies cite that the prevalence of this condition increases with age. This information is provided by Fortune...

Continue reading

AGF Management Limited Reports Third Quarter 2023 Financial Results

TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) —Reported quarterly diluted earnings per share of $0.34 AGF reported mutual fund net redemptions of $151 million AGF saw growth of 43% in its ETFs and SMA AUM year over year Quarterly dividend of $0.11 per shareAGF Management Limited (AGF or the Company) (TSX: AGF.B) today announced financial results for the third quarter ended August 31, 2023. AGF reported total assets under management and fee-earning assets1 of $42.3 billion compared to $41.2 billion as at May 31, 2023 and $39.6 billion as at August 31, 2022. “We continue to see the results of implementing our long-term strategic plan to diversify our business across asset classes and client channels allowing us to persevere through different market cycles,” said Kevin McCreadie, Chief Executive Officer and Chief Investment Officer,...

Continue reading

Integrated Wellness Acquisition Corp Announces Termination of Merger Agreement

NEW YORK, NY, Sept. 27, 2023 (GLOBE NEWSWIRE) — Integrated Wellness Acquisition Corp (NYSE: WEL) (the “Company”) announced that it notified Refreshing USA, LLC, that the Company had elected to terminate the Agreement and Plan of Merger among the parties, dated as of February 10, 2023 (the “Merger Agreement”), effective immediately, pursuant to Section 8.1(b) thereof, since the conditions to the closing of the initial business combination were not satisfied or waived by the outside date of July 31, 2023 (the “Termination”). As a result, the Merger Agreement is of no further force and effect, with the exception of certain specified provisions in the Merger Agreement, which shall survive the Termination and remain in full force and effect in accordance with their respective terms. The Company and its sponsor intend to seek alternative...

Continue reading

Revival Gold Reports Initial 2023 Exploration Results

Figure 12023 Beartrack-Arnett Drill ProgramTORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), is pleased to report on the Company’s 2023 exploration campaign at the Beartrack-Arnett Gold Project (“Beartrack-Arnett” or the “Project”) located in Lemhi County, Idaho, USA. HighlightsRevival Gold has completed 15 holes and 3,100 meters of this season’s drill program. Assay results have been received for the first two drill holes (AC23-103D and AC23-104D) located in the Roman’s Trench target area.AC23-104D intersected 0.66 g/t gold over 7.0 meters drilled width and 3.1 g/t gold over 0.7 meters drilled width.   AC23-103D encountered quartz-iron oxide veinlets, but no significant gold mineralization.In addition to drilling at Roman’s Trench, Revival...

Continue reading

Aéroports de Paris SA – Groupe ADP took note of the French government’s proposal for a new tax applicable to certain major transport infrastructure in France, including ADP SA’s

FINANCIAL RELEASE September 27th, 2023  Aéroports de Paris SAGroupe ADP took note of the French government’s proposal for a new tax applicable to certain major transport infrastructure in France, including ADP SA’s Groupe ADP took note of the finance bill for 2024, adopted today by the Council of Ministers. The bill plans to introduce a new tax applicable to certain French transport infrastructure companies, including Aéroports de Paris SA (ADP SA). The bill provides for a 4.6% tax applicable to the revenue, as stated in Aéroport de Paris SA’s annual accounts, notably excluding revenues from airport safety and security services, and after the deduction of a 120 million euros exemption. The tax base would therefore have been 2,175 million euros as of December 31st, 20221 (to be compared with 2022 consolidated revenue of...

Continue reading

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene. “We are delighted to have been granted the European Patent for our PD1-41BB CSP, one of the key technologies of Medigene’s End-to-End (E2E) Platform. This complements our PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan, and strengthens our patent portfolio worldwide,” said Selwyn Ho,...

Continue reading

IBA finalizes contract with Medtechnica Ltd for two Proteus®ONE proton therapy solutions at the Tel Aviv Sourasky Medical Center in Israel  

Louvain-La-Neuve, Belgium, September 27, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed the final contract with Medtechnica Ltd for the installation of two Proteus®ONE1compact proton therapy solutions at the Sourasky Medical Center (Ichilov Hospital) in Tel Aviv, Israel. This follows the signature of a binding term sheet previously announced in May 2023. Sourasky Medical Center has been selected by the Israeli Ministry of Health to host the first national proton therapy center in Israel, bringing this cutting-edge technology to hundreds of patients per year. The project is fully financed and IBA received the first payment in July 2023. The integrated solution...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.